Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depressive breakthrough.

A A Nierenberg1, J E Alpert

  • 1Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.

The Psychiatric Clinics of North America
|January 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.

Journal of affective disorders·2019
Same author

Face and predictive validity of the ClockΔ19 mouse as an animal model for bipolar disorder: a systematic review.

Molecular psychiatry·2017
Same author

Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1].

Journal of affective disorders·2017
Same author

Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEP-BD study.

Acta psychiatrica Scandinavica·2017
Same author

Physical Exercise for Treatment of Mood Disorders: A Critical Review.

Current behavioral neuroscience reports·2017
Same author

Predictive analytics in mental health: applications, guidelines, challenges and perspectives.

Molecular psychiatry·2016
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

Antidepressant therapy prevents relapse, but breakthrough depression occurs. Further research is needed on optimal strategies for managing recurrent depression during long-term treatment.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Antidepressant pharmacotherapy is effective for preventing relapse and recurrence of depression.
  • Despite long-term treatment, substantial rates of relapse and recurrence persist.
  • Management strategies for breakthrough depression lack controlled trial data.

Purpose of the Study:

  • To review the current understanding of managing breakthrough depression.
  • To highlight the need for controlled studies on re-emergent depression management.

Main Methods:

  • Review of controlled and observational studies on antidepressant pharmacotherapy.
  • Analysis of existing literature on strategies for managing breakthrough depression.

Main Results:

Related Experiment Videos

  • Antidepressant maintenance at full remission doses is advantageous.
  • Significant rates of relapse and recurrence occur despite continuous treatment.
  • Three primary pharmacologic strategies for breakthrough depression include dose increase, augmentation, or switching agents.

Conclusions:

  • Controlled studies are essential to determine optimal treatment sequences for re-emergent depression.
  • Further research should define symptom thresholds for initiating interventions in recurrent depression.